Archives

FDA takes aim at Hims & Hers, weight loss drugs in new advertising blitz

The Food and Drug Administration seal is seen at the Hubert Humphrey Building Auditorium in Washington, April 22, 2025. (AP Photo/Jose Luis Magana, File) 2025-09-16T15:21:19Z WASHINGTON (AP) — For the first time, federal health officials are taking aim at telehealth companies promoting unofficial versions of prescription drugs — including popular weight loss medications — as […]

Will Rybelsus’ Updated EU Label Propel Fresh Growth Potential for NVO?

Novo Nordisk NVO has secured European approval to update the label of oral GLP-1 drug for type II diabetes (T2D), Rybelsus (oral semaglutide), to reflect cardiovascular benefits demonstrated in the phase IIIb SOUL study. The late-stage study, involving 9,650 patients with T2D and atherosclerotic cardiovascular and/or chronic kidney disease, showed that Rybelsus cut the risk of […]

Novo Nordisk’s non-GLP-1 drug cuts body weight by over 11% in trial

Novo Nordisk reported results from its phase 3 clinical trial for its experimental obesity drug cagrilintide which showed significant weight loss among participants.  The research, presented at the 2025 European Association for the Study of Diabetes congress in Vienna, found that participants receiving once-weekly monotherapy injections of 2.4 mg cagrilintide, an amylin analogue, lost an […]

This weight-loss pill by Lilly could be FDA-approved by end of 2025

Eli Lilly’s experimental weight-loss pill could be fast-tracked under a one- to two-month review process recently launched by the U.S. Food and Drug Administration, several Wall Street analysts said. Analysts speculate that the drug, orforglipron, is a viable candidate given the growing cost burden of expensive injectable weight-loss drugs and the fact that Lilly is […]

FDA takes aim at Hims and other telehealth services in drug advertising blitz

By MATTHEW PERRONE, AP Health Writer WASHINGTON (AP) — For the first time, federal health officials are taking aim at telehealth companies promoting unofficial versions of prescription drugs — including popular weight loss medications — as part of the Trump administration’s crackdown on pharmaceutical advertising. The Food and Drug Administration on Tuesday posted more than […]

Half Discontinue Semaglutide for Weight Loss Within One Year

TUESDAY, Sept. 16, 2025 — Half of adults who start semaglutide for weight loss discontinue within a year, according to a study presented at the annual meeting of the European Association for the Study of Diabetes, held from Sept. 15 to 19 in…